Eli Radiopharma Raises RMB 100 Million in Angel Funding Round to Accelerate Its Radiopharmaceutical Innovation and Strategic Growth

Hangzhou, China - December 24, 2024 - Hangzhou Eli Radiopharma Co., Ltd. ("Eli Radiopharma", the "Company"), a radiopharmaceutical company dedicated to innovative targeted radionuclide therapy with theranostics, today announced that it has raised RMB 100 million in an angel funding round to develop a cutting-edge radiopharmaceutical innovation platform, increase its research and development capabilities, accelerate Company's clinical programs, and expand the team.

The funding round was led by TaiLong VC and Yuanbio Venture Capital, along with Tsing Song Capital, TigerYeah Capital, BOHE Angel Fund, and Lula Capital. The funding marks a significant milestone in Eli Radiopharma's vision and its commitment to achieving the strategic goal of theranostics while establishing a solid foundation for future growth and development.

"We are thrilled by the strong support from our investors, which reflects their confidence in Eli Radiopharma's ability to be innovative and the potential of radiopharmaceuticals development," said Dr. Feng Yu, CEO of Eli Radiopharma, "Eli Radiopharma's core rationale is precision medicine, we will drive our discovery by exploring novel targets, incorporating new chemical entities, and new radionuclides into a broader range of disease indications. With our highly-skilled team and expertise from our collaborating partners, the focus remains on developing breakthrough therapies that deliver differentiated solutions for patients, while accelerating the advancement of radiopharmaceuticals in China and globally, ultimately contributing to improving human health."

About Eli Radiopharma

Eli Radiopharma, founded in 2024, is a radiopharmaceutical company specializing in innovating and developing radiopharmaceuticals and advanced technology applications. Established by a team of experienced scientists and entrepreneurs, the company focuses on oncology and neuroscience. Driven by its core value of  'Innovation-driven, Precision Medicine', Eli Radiopharma is committed to developing cutting-edge radiopharmaceuticals to provide precise diagnostics and effective treatments to improve the health and longevity of patients worldwide.